Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Sushree Mohanty

Is This Dividend Stock a Buy After Better-Than-Expected Q4 Results?

Pfizer (PFE) is a pharmaceutical and biotechnology company valued at $145 billion by market capitalization. While the company is more recently renowned for its COVID-19 vaccine, it also develops medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. 

Despite a positive fourth-quarter report that beat consensus estimates, Pfizer stock is down 3.2% year-to-date, compared to the S&P 500 Index’s ($SPX) gain of 4.2%. Let’s find out if Pfizer stock is a good buy now.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.